Published in Virol J on May 06, 2005
High-efficiency transduction of the mouse retina by tyrosine-mutant AAV serotype vectors. Mol Ther (2008) 2.93
Optimizing promoters for recombinant adeno-associated virus-mediated gene expression in the peripheral and central nervous system using self-complementary vectors. Hum Gene Ther (2011) 1.90
Recurrent AAV2-related insertional mutagenesis in human hepatocellular carcinomas. Nat Genet (2015) 1.86
Inner limiting membrane barriers to AAV-mediated retinal transduction from the vitreous. Mol Ther (2009) 1.73
Recombinant adeno-associated virus vectors induce functionally impaired transgene product-specific CD8+ T cells in mice. J Clin Invest (2007) 1.57
Enhancement of adeno-associated virus infection by mobilizing capsids into and out of the nucleolus. J Virol (2008) 1.50
Adipose tissue-derived mesenchymal stem cell-based liver gene delivery. J Hepatol (2010) 1.50
The Mre11/Rad50/Nbs1 complex limits adeno-associated virus transduction and replication. J Virol (2007) 1.46
A novel adeno-associated viral variant for efficient and selective intravitreal transduction of rat Müller cells. PLoS One (2009) 1.40
Progress in gene therapy for neurological disorders. Nat Rev Neurol (2013) 1.22
Stimulation of homology-directed gene targeting at an endogenous human locus by a nicking endonuclease. Nucleic Acids Res (2009) 1.19
Capsid serotype and timing of injection determines AAV transduction in the neonatal mice brain. PLoS One (2013) 1.19
Improved survival and reduced phenotypic severity following AAV9/MECP2 gene transfer to neonatal and juvenile male Mecp2 knockout mice. Mol Ther (2012) 1.16
Ultramicroscopy reveals axonal transport impairments in cortical motor neurons at prion disease. Biophys J (2009) 1.00
Viral vectors and delivery strategies for CNS gene therapy. Ther Deliv (2010) 0.98
Sustained induction of neuronal addition to the adult rat neostriatum by AAV4-delivered noggin and BDNF. Gene Ther (2011) 0.95
Transduction of the central nervous system after intracerebroventricular injection of adeno-associated viral vectors in neonatal and juvenile mice. Hum Gene Ther Methods (2013) 0.94
The mechanism of gene targeting in human somatic cells. PLoS Genet (2014) 0.94
Advances in AAV vector development for gene therapy in the retina. Adv Exp Med Biol (2014) 0.94
A common mechanism for cytoplasmic dynein-dependent microtubule binding shared among adeno-associated virus and adenovirus serotypes. J Virol (2006) 0.93
Induction of rapid and highly efficient expression of the human ND4 complex I subunit in the mouse visual system by self-complementary adeno-associated virus. Arch Ophthalmol (2010) 0.93
Blocking translocation of cell surface molecules from the ER to the cell surface by intracellular antibodies targeted to the ER. J Cell Mol Med (2007) 0.90
The role of infection in miscarriage. Hum Reprod Update (2015) 0.89
Clinical applications involving CNS gene transfer. Adv Genet (2014) 0.89
Targeted chromosomal insertion of large DNA into the human genome by a fiber-modified high-capacity adenovirus-based vector system. PLoS One (2008) 0.88
Self-complementary AAVs induce more potent transgene product-specific immune responses compared to a single-stranded genome. Mol Ther (2011) 0.85
Engineered Viruses as Genome Editing Devices. Mol Ther (2015) 0.84
Bioengineered coagulation factor VIII enables long-term correction of murine hemophilia A following liver-directed adeno-associated viral vector delivery. Mol Ther Methods Clin Dev (2014) 0.83
Host Anti-antibody Responses Following Adeno-associated Virus-mediated Delivery of Antibodies Against HIV and SIV in Rhesus Monkeys. Mol Ther (2015) 0.83
Nonspaced inverted DNA repeats are preferential targets for homology-directed gene repair in mammalian cells. Nucleic Acids Res (2011) 0.82
NADH-dehydrogenase type-2 suppresses irreversible visual loss and neurodegeneration in the EAE animal model of MS. Mol Ther (2013) 0.82
Transduction, tropism, and biodistribution of AAV vectors in the lacrimal gland. Invest Ophthalmol Vis Sci (2011) 0.81
Promise and problems associated with the use of recombinant AAV for the delivery of anti-HIV antibodies. Mol Ther Methods Clin Dev (2016) 0.80
Formation of AAV single stranded DNA genome from a circular plasmid in Saccharomyces cerevisiae. PLoS One (2011) 0.80
Preclinical toxicity evaluation of AAV for pain: evidence from human AAV studies and from the pharmacology of analgesic drugs. Mol Pain (2014) 0.80
Concerted nicking of donor and chromosomal acceptor DNA promotes homology-directed gene targeting in human cells. Nucleic Acids Res (2011) 0.80
Recombinant AAV Vectors for Enhanced Expression of Authentic IgG. PLoS One (2016) 0.77
Characterization of naturally-occurring humoral immunity to AAV in sheep. PLoS One (2013) 0.77
Pseudotyped adeno-associated virus 2/9-delivered CCL11 shRNA alleviates lung inflammation in an allergen-sensitized mouse model. Hum Gene Ther (2012) 0.77
Gene targeting in ischemic heart disease and failure: translational and clinical studies. Biochem Pharmacol (2012) 0.77
Adeno-associated virus type 2 as an oncogenic virus in human hepatocellular carcinoma. Mol Cell Oncol (2016) 0.76
Proliferation of Multiple Cell Types in the Skeletal Muscle Tissue Elicited by Acute p21 Suppression. Mol Ther (2015) 0.75
Effects of interferon-γ knockdown on vaccine-induced immunity against Marek's disease in chickens. Can J Vet Res (2015) 0.75
Intrathecal administration of AAV/GALC vectors in 10-11-day-old twitcher mice improves survival and is enhanced by bone marrow transplant. J Neurosci Res (2016) 0.75
Altering the genome by homologous recombination. Science (1989) 12.73
Novel adeno-associated viruses from rhesus monkeys as vectors for human gene therapy. Proc Natl Acad Sci U S A (2002) 11.11
ADENOVIRUS-ASSOCIATED DEFECTIVE VIRUS PARTICLES. Science (1965) 9.77
Membrane-associated heparan sulfate proteoglycan is a receptor for adeno-associated virus type 2 virions. J Virol (1998) 8.45
Production of high-titer recombinant adeno-associated virus vectors in the absence of helper adenovirus. J Virol (1998) 7.76
Site-specific integration by adeno-associated virus. Proc Natl Acad Sci U S A (1990) 7.06
Second-strand synthesis is a rate-limiting step for efficient transduction by recombinant adeno-associated virus vectors. J Virol (1996) 6.22
Targeted integration of adeno-associated virus (AAV) into human chromosome 19. EMBO J (1991) 6.13
The AAV origin binding protein Rep68 is an ATP-dependent site-specific endonuclease with DNA helicase activity. Cell (1990) 5.98
Transduction with recombinant adeno-associated virus for gene therapy is limited by leading-strand synthesis. J Virol (1996) 5.94
Cloning of adeno-associated virus into pBR322: rescue of intact virus from the recombinant plasmid in human cells. Proc Natl Acad Sci U S A (1982) 5.73
Systemic delivery of genes to striated muscles using adeno-associated viral vectors. Nat Med (2004) 5.59
Human fibroblast growth factor receptor 1 is a co-receptor for infection by adeno-associated virus 2. Nat Med (1999) 5.50
AlphaVbeta5 integrin: a co-receptor for adeno-associated virus type 2 infection. Nat Med (1999) 5.26
Adeno-associated virus terminal repeat (TR) mutant generates self-complementary vectors to overcome the rate-limiting step to transduction in vivo. Gene Ther (2003) 4.92
Real-time single-molecule imaging of the infection pathway of an adeno-associated virus. Science (2001) 4.61
Long-term correction of canine hemophilia B by gene transfer of blood coagulation factor IX mediated by adeno-associated viral vector. Nat Med (1999) 4.61
AAV-mediated factor IX gene transfer to skeletal muscle in patients with severe hemophilia B. Blood (2002) 4.60
Self-complementary recombinant adeno-associated virus (scAAV) vectors promote efficient transduction independently of DNA synthesis. Gene Ther (2001) 4.35
The atomic structure of adeno-associated virus (AAV-2), a vector for human gene therapy. Proc Natl Acad Sci U S A (2002) 4.30
Novel tools for production and purification of recombinant adenoassociated virus vectors. Hum Gene Ther (1998) 4.03
A viral phospholipase A2 is required for parvovirus infectivity. Dev Cell (2001) 3.97
Use of adeno-associated virus as a mammalian DNA cloning vector: transduction of neomycin resistance into mammalian tissue culture cells. Proc Natl Acad Sci U S A (1984) 3.92
Insect cells as a factory to produce adeno-associated virus type 2 vectors. Hum Gene Ther (2002) 3.92
Infectious entry pathway of adeno-associated virus and adeno-associated virus vectors. J Virol (2000) 3.84
Adeno-associated virus vectors can be efficiently produced without helper virus. Gene Ther (1998) 3.77
Rapid uncoating of vector genomes is the key to efficient liver transduction with pseudotyped adeno-associated virus vectors. J Virol (2004) 3.65
Stable in vivo expression of the cystic fibrosis transmembrane conductance regulator with an adeno-associated virus vector. Proc Natl Acad Sci U S A (1993) 3.59
Adeno-associated virus (AAV) Rep proteins mediate complex formation between AAV DNA and its integration site in human DNA. Proc Natl Acad Sci U S A (1994) 3.59
Factors that bind to adeno-associated virus terminal repeats. J Virol (1989) 3.56
Mapping and direct visualization of a region-specific viral DNA integration site on chromosome 19q13-qter. Genomics (1991) 3.47
Correction of hemophilia B in canine and murine models using recombinant adeno-associated viral vectors. Nat Med (1999) 3.39
Extrachromosomal recombinant adeno-associated virus vector genomes are primarily responsible for stable liver transduction in vivo. J Virol (2001) 3.38
Parvovirus replication. Microbiol Rev (1990) 3.37
Unrestricted hepatocyte transduction with adeno-associated virus serotype 8 vectors in mice. J Virol (2005) 3.28
Quantitative analysis of the packaging capacity of recombinant adeno-associated virus. Hum Gene Ther (1996) 3.26
Adeno-associated virus serotype 4 (AAV4) and AAV5 both require sialic acid binding for hemagglutination and efficient transduction but differ in sialic acid linkage specificity. J Virol (2001) 3.11
Human gene targeting by viral vectors. Nat Genet (1998) 3.02
Self-complementarity of terminal sequences within plus or minus strands of adenovirus-associated virus DNA. Proc Natl Acad Sci U S A (1973) 2.96
Mutagenesis of an AUG codon in the adeno-associated virus rep gene: effects on viral DNA replication. Virology (1989) 2.91
AAV serotype 2 vectors preferentially integrate into active genes in mice. Nat Genet (2003) 2.81
The recombination signals for adeno-associated virus site-specific integration. Proc Natl Acad Sci U S A (1996) 2.74
Isolation of highly infectious and pure adeno-associated virus type 2 vectors with a single-step gravity-flow column. Hum Gene Ther (2001) 2.69
Features of the adeno-associated virus origin involved in substrate recognition by the viral Rep protein. J Virol (1993) 2.69
DNA-damaging agents greatly increase the transduction of nondividing cells by adeno-associated virus vectors. J Virol (1994) 2.50
The VP1 capsid protein of adeno-associated virus type 2 is carrying a phospholipase A2 domain required for virus infectivity. J Gen Virol (2002) 2.44
DNA helicase-mediated packaging of adeno-associated virus type 2 genomes into preformed capsids. EMBO J (2001) 2.43
Identification of PDGFR as a receptor for AAV-5 transduction. Nat Med (2003) 2.43
In vivo model of adeno-associated virus vector persistence and rescue. J Virol (1996) 2.41
Biology of adeno-associated virus. Curr Top Microbiol Immunol (1996) 2.40
DNA amplification of adeno-associated virus as a response to cellular genotoxic stress. Cancer Res (1988) 2.39
A human parvovirus, adeno-associated virus, as a eucaryotic vector: transient expression and encapsidation of the procaryotic gene for chloramphenicol acetyltransferase. Mol Cell Biol (1984) 2.36
Sequence requirements for binding of Rep68 to the adeno-associated virus terminal repeats. J Virol (1996) 2.32
Subcellular compartmentalization of adeno-associated virus type 2 assembly. J Virol (1997) 2.31
Adeno-associated virus vectors integrate at chromosome breakage sites. Nat Genet (2004) 2.27
Asymmetric replication in vitro from a human sequence element is dependent on adeno-associated virus Rep protein. J Virol (1995) 2.23
Role for highly regulated rep gene expression in adeno-associated virus vector production. J Virol (1997) 2.19
Separation of two types of adeno-associated virus particles containing complementary polynucleotide chains. J Virol (1972) 2.15
From virus evolution to vector revolution: use of naturally occurring serotypes of adeno-associated virus (AAV) as novel vectors for human gene therapy. Curr Gene Ther (2003) 2.12
Sustained correction of disease in naive and AAV2-pretreated hemophilia B dogs: AAV2/8-mediated, liver-directed gene therapy. Blood (2005) 2.12
Recruitment of single-stranded recombinant adeno-associated virus vector genomes and intermolecular recombination are responsible for stable transduction of liver in vivo. J Virol (2000) 2.00
Dynamin is required for recombinant adeno-associated virus type 2 infection. J Virol (1999) 1.99
Hepatocyte growth factor receptor is a coreceptor for adeno-associated virus type 2 infection. J Virol (2005) 1.97
The adeno-associated virus (AAV) Rep protein acts as both a repressor and an activator to regulate AAV transcription during a productive infection. J Virol (1997) 1.89
Concatamerization of adeno-associated virus circular genomes occurs through intermolecular recombination. J Virol (1999) 1.84
A phase I study of an adeno-associated virus-CFTR gene vector in adult CF patients with mild lung disease. Hum Gene Ther (1996) 1.80
Adenovirus-facilitated nuclear translocation of adeno-associated virus type 2. J Virol (2002) 1.77
Gene targeting in stem cells from individuals with osteogenesis imperfecta. Science (2004) 1.75
Phosphorylation of a novel myosin binding subunit of protein phosphatase 1 reveals a conserved mechanism in the regulation of actin cytoskeleton. J Biol Chem (2001) 1.72
High-titer adeno-associated viral vectors from a Rep/Cap cell line and hybrid shuttle virus. Hum Gene Ther (1998) 1.68
The Rep52 gene product of adeno-associated virus is a DNA helicase with 3'-to-5' polarity. J Virol (1998) 1.61
Scalable purification of adeno-associated virus type 2, 4, or 5 using ion-exchange chromatography. Hum Gene Ther (2002) 1.60
A phase I study of aerosolized administration of tgAAVCF to cystic fibrosis subjects with mild lung disease. Hum Gene Ther (2001) 1.58
Adeno-associated virus type 2-mediated gene transfer: role of cellular FKBP52 protein in transgene expression. J Virol (2001) 1.58
Assembly of viruslike particles by recombinant structural proteins of adeno-associated virus type 2 in insect cells. J Virol (1992) 1.52
Safety of single-dose administration of an adeno-associated virus (AAV)-CFTR vector in the primate lung. Gene Ther (1996) 1.45
Effect of DNA-dependent protein kinase on the molecular fate of the rAAV2 genome in skeletal muscle. Proc Natl Acad Sci U S A (2001) 1.45
Cellular proteins required for adeno-associated virus DNA replication in the absence of adenovirus coinfection. J Virol (1998) 1.39
Infection of purified nuclei by adeno-associated virus 2. Mol Ther (2001) 1.37
Roles of adeno-associated virus Rep protein and human chromosome 19 in site-specific recombination. J Virol (2000) 1.37
High-titer recombinant adeno-associated virus production utilizing a recombinant herpes simplex virus type I vector expressing AAV-2 Rep and Cap. Gene Ther (1999) 1.34
Site-specific integration mediated by a hybrid adenovirus/adeno-associated virus vector. Proc Natl Acad Sci U S A (1999) 1.32
Cystic fibrosis and the salt controversy. Cell (1999) 1.31
A p5 integration efficiency element mediates Rep-dependent integration into AAVS1 at chromosome 19. Proc Natl Acad Sci U S A (2002) 1.31
Efficient trans-splicing in the retina expands the utility of adeno-associated virus as a vector for gene therapy. Hum Gene Ther (2003) 1.29
Involvement of cellular double-stranded DNA break binding proteins in processing of the recombinant adeno-associated virus genome. J Virol (2001) 1.29
Site-specific integration in mammalian cells mediated by a new hybrid baculovirus-adeno-associated virus vector. J Virol (1998) 1.28
Efficient recombinant adeno-associated virus production by a stable rep-cap HeLa cell line correlates with adenovirus-induced amplification of the integrated rep-cap genome. J Gene Med (2000) 1.23
Loss of ATM function enhances recombinant adeno-associated virus transduction and integration through pathways similar to UV irradiation. Virology (2000) 1.23
Efficient integration of recombinant adeno-associated virus DNA vectors requires a p5-rep sequence in cis. J Virol (2002) 1.21
Adeno-associated virus (AAV) site-specific recombination does not require a Rep-dependent origin of replication within the AAV terminal repeat. Proc Natl Acad Sci U S A (2001) 1.21
Inverted terminal repeat sequences are important for intermolecular recombination and circularization of adeno-associated virus genomes. J Virol (2005) 1.21
Building a better vector: the manipulation of AAV virions. Virology (2000) 1.19
Posttranslational modifications of recombinant myotube-synthesized human factor IX. Blood (2001) 1.18
Identification of an insulator in AAVS1, a preferred region for integration of adeno-associated virus DNA. J Virol (2003) 1.18
Mechanism of Rep-mediated adeno-associated virus origin nicking. J Virol (2000) 1.17
Intracellular viral processing, not single-stranded DNA accumulation, is crucial for recombinant adeno-associated virus transduction. J Virol (2004) 1.17
Consequences of DNA-dependent protein kinase catalytic subunit deficiency on recombinant adeno-associated virus genome circularization and heterodimerization in muscle tissue. J Virol (2003) 1.16